Prev Arrow Stocks

Hormel Foods Corporation ($HRL) Stock Forecast: Up 5.2% Today

Morpher AI identified a bullish signal. The stock price may continue to rise based on the momentum of the good news.

What is Hormel Foods Corporation?

Hormel Foods Corporation (HRL) is a well-known food company that focuses on value-added protein products, with its Jennie-O brand being a prominent player in the market. Today, the stock of HRL experienced a strong bullish movement.

Why is Hormel Foods Corporation going up?

HRL stock is up 5.2% on Feb 18, 2026 15:56

  • Hormel Foods Corporation's decision to sell its whole-bird turkey business to Life-Science Innovations is seen as a strategic move to reduce exposure to volatile commodity markets and focus on its value-added protein portfolio.
  • The sale of the turkey business aligns with Hormel's portfolio shaping efforts and financial performance expectations, as evidenced by the company's preliminary Q1 adjusted earnings projections beating estimates.
  • Investors seem to be reacting positively to Hormel's strategic decision, as the company forecasts continued organic sales growth and reaffirms its fiscal 2026 guidance, indicating a solid start to the year and potential for long-term profitable growth.
  • Overall, the market's bullish reaction to Hormel's strategic moves reflects confidence in the company's ability to adapt to market dynamics and drive value for shareholders.

HRL Price Chart

HRL Technical Analysis

HRL News

Hormel selling whole-bird turkey business

Hormel Foods Corp. is selling its whole-bird turkey business to Life-Science Innovations (LSI) to reduce its exposure to volatile commodity markets and focus on value-added protein products. The transaction includes a production facility and feed mill in Minnesota, and LSI will provide co-manufacturing services during a transition period. The Jennie-O brand name and its broader product line are not affected by this sale.

https://www.feedstuffs.com/agribusiness-news/hormel-selling-whole-bird-turkey-business

0 Missing News Article Image Hormel selling whole-bird turkey business

Hormel Foods Sells Whole-Bird Turkey Business to Life-Science Innovations

Hormel Foods Corporation has agreed to sell its whole-bird turkey business to Life-Science Innovations (LSI) to focus on its value-added protein portfolio. The transaction, expected to close by the end of Hormel's fiscal second quarter 2026, includes production facilities and supply contracts, but does not impact the broader JENNIE-O brand. Hormel will also provide co-manufacturing services to LSI during the transition period.

https://www.foodengineeringmag.com/articles/103537-hormel-foods-sells-whole-bird-turkey-business-to-life-science-innovations

1 News Article Image Hormel Foods Sells Whole-Bird Turkey Business to Life-Science Innovations

Hormel (NYSE: HRL) posts Q1 prelims and sells whole-bird turkey unit

Hormel Foods Corporation reported preliminary first quarter fiscal 2026 results, expecting net sales of approximately $3 billion and reaffirming its fiscal 2026 guidance. The company also announced a definitive agreement to sell its whole-bird turkey business to Life-Science Innovations, with minimal estimated impact on its 2026 financial guidance. These moves are part of Hormel's portfolio shaping efforts and reflect a solid start to the year, aiming for long-term profitable growth.

https://www.stocktitan.net/sec-filings/HRL/8-k-hormel-foods-corp-de-reports-material-event-3ebc9eabd416.html

2 News Article Image Hormel (NYSE: HRL) posts Q1 prelims and sells whole-bird turkey unit

Hormel Foods' Preliminary Q1 Adjusted Earnings Projections Beat Estimates; Sells Minnesota Turkey Assets to Life-Science Innovations

Hormel Foods announced preliminary adjusted earnings projections for Q1 2026 that exceeded analyst estimates. Concurrently, the company has entered a definitive agreement to sell its Minnesota turkey assets, which include its whole-bird turkey business, to Life-Science Innovations. This strategic move aligns with Hormel's portfolio management and financial performance expectations.

https://www.marketscreener.com/news/hormel-foods-preliminary-q1-adjusted-earnings-projections-beat-estimates-sells-minnesota-turkey-as-ce7e5ddedb80f321

3 News Article Image Hormel Foods' Preliminary Q1 Adjusted Earnings Projections Beat Estimates; Sells Minnesota Turkey Assets to Life-Science Innovations

Hormel Foods sells whole-bird turkey business, forecasts continued organic sales growth (HRL:NYSE)

Hormel Foods (HRL) has announced the sale of its whole-bird turkey business to Life-Science Innovations. Concurrently, the company projects approximately $3 billion in net sales for the first quarter of fiscal 2026, which would represent its fifth consecutive quarter of year-over-year organic growth.

https://seekingalpha.com/news/4552998-hormel-foods-sells-whole-bird-turkey-business-forecasts-continued-organic-sales-growth

4 News Article Image Hormel Foods sells whole-bird turkey business, forecasts continued organic sales growth (HRL:NYSE)

Hormel Foods Corporation Price History

14.00.2026 - HRL Stock was up 5.1%

  • The retirement announcements of two veteran executives, Mark Morey and Paul Peil, may have been perceived positively by investors, signaling potential for fresh leadership and strategic changes within the company.
  • The increase in stake by Sumitomo Mitsui DS Asset Management Company Ltd could have instilled confidence in the market, indicating a strong belief in Hormel's future growth prospects.
  • Despite missing revenue estimates, the company's Q3 EPS beat analyst expectations, showcasing operational efficiency and resilience in challenging market conditions.
  • The upcoming annual meeting of stockholders and the related gift boxes at the SPAM Museum might have generated excitement and positive sentiment around the company, contributing to the bullish movement in the stock price.

18.01.2026 - HRL Stock was up 5.2%

  • Hormel Foods Corporation's decision to sell its whole-bird turkey business to Life-Science Innovations is seen as a strategic move to reduce exposure to volatile commodity markets and focus on its value-added protein portfolio.
  • The sale of the turkey business aligns with Hormel's portfolio shaping efforts and financial performance expectations, as evidenced by the company's preliminary Q1 adjusted earnings projections beating estimates.
  • Investors seem to be reacting positively to Hormel's strategic decision, as the company forecasts continued organic sales growth and reaffirms its fiscal 2026 guidance, indicating a solid start to the year and potential for long-term profitable growth.
  • Overall, the market's bullish reaction to Hormel's strategic moves reflects confidence in the company's ability to adapt to market dynamics and drive value for shareholders.

04.11.2025 - HRL Stock was up 7.6%

  • The company reported a Q4 profit beat and raised its forecast for the upcoming year, estimating a growth in earnings per share of 4% to 10%. This optimistic projection influenced the stock's upward trend.
  • Hormel's Q4 adjusted EPS of $0.32 per share surpassed expectations, signaling a strong financial performance for the quarter and bolstering investor confidence.
  • Despite encountering challenges such as input cost inflation and impairment charges, Hormel achieved a 2% rise in organic net sales for the fiscal year, further reinforcing the positive market sentiment.
  • The improved sales outlook for 2026, accompanied by a dividend increase announcement, highlighted Hormel's resilience and strategic planning, propelling the stock price higher.
i
Disclaimer
Morpher is not liable for the content of the AI investment insights. Like most GPT-powered tools, these summaries may contain AI hallucinations and inaccurate information. Morpher is not presenting you with any investment advice. All investments involve risk, and the past performance of a security, industry, sector, market, or financial product does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. Such decisions should be based solely on an evaluation of their financial circumstances, investment objectives, risk tolerance, and liquidity needs. These summaries do not constitute investment advice.